BACKGROUND: Premature bone loss after childhood chemotherapy may be underestimated in patients with bone sarcoma. Methotrexate (MTX), a standard agent in osteosarcoma protocols, reportedly reduces bone mineral density (BMD). The literature, however, has reported cases of BMD reduction in patients with Ewing's sarcoma treated without MTX. Thus, it is unclear whether osteoporosis after chemotherapy relates to MTX or to other factors. QUESTIONS/PURPOSES: We therefore asked whether (1) young patients with a bone sarcoma had BMD reduction, (2) patients treated with MTX had lower BMD, and (3) other factors (eg, lactose intolerance or vitamin D deficiency) posed additional risks for low BMD. METHODS: We retrospectively reviewed 43 patients with malignancies who had dual-energy x-ray absorptiometry (DEXA) (lumbar, femoral); 18 with Ewing's sarcoma (mean age, 26 ± 8 years), and 25 with an osteosarcoma (mean age, 27 ± 10 years). The mean time since diagnosis was 8 ± 4 years in the group with Ewing's sarcoma and 7 ± 5 years in the group with osteosarcoma. At last followup we determined BMD (computing z-scores), fracture rate, and lifestyle, and performed serum analysis. RESULTS: BMD reduction was present in 58% of patients (37% had a z-score between -1 and -2 SD, 21% had a z-score less than -2 SD) in at least one measured site. Seven of the 43 patients (16%) had nontrauma or tumor-associated fractures after chemotherapy. Findings were similar in the Ewing and osteosarcoma subgroups. We found vitamin D deficiency in 38 patients (88%) and borderline elevated bone metabolism; lactose intolerance was present in 16 patients (37%). CONCLUSION: Doctors should be aware of the possibility of major bone loss after chemotherapy with a risk of pathologic fracture. Vitamin D deficiency, calcium malnutrition, and lactose intolerance may potentiate the negative effects of chemotherapy, and should be considered in long-term patient management. LEVEL OF EVIDENCE: Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
BACKGROUND:Premature bone loss after childhood chemotherapy may be underestimated in patients with bone sarcoma. Methotrexate (MTX), a standard agent in osteosarcoma protocols, reportedly reduces bone mineral density (BMD). The literature, however, has reported cases of BMD reduction in patients with Ewing's sarcoma treated without MTX. Thus, it is unclear whether osteoporosis after chemotherapy relates to MTX or to other factors. QUESTIONS/PURPOSES: We therefore asked whether (1) young patients with a bone sarcoma had BMD reduction, (2) patients treated with MTX had lower BMD, and (3) other factors (eg, lactose intolerance or vitamin D deficiency) posed additional risks for low BMD. METHODS: We retrospectively reviewed 43 patients with malignancies who had dual-energy x-ray absorptiometry (DEXA) (lumbar, femoral); 18 with Ewing's sarcoma (mean age, 26 ± 8 years), and 25 with an osteosarcoma (mean age, 27 ± 10 years). The mean time since diagnosis was 8 ± 4 years in the group with Ewing's sarcoma and 7 ± 5 years in the group with osteosarcoma. At last followup we determined BMD (computing z-scores), fracture rate, and lifestyle, and performed serum analysis. RESULTS:BMD reduction was present in 58% of patients (37% had a z-score between -1 and -2 SD, 21% had a z-score less than -2 SD) in at least one measured site. Seven of the 43 patients (16%) had nontrauma or tumor-associated fractures after chemotherapy. Findings were similar in the Ewing and osteosarcoma subgroups. We found vitamin D deficiency in 38 patients (88%) and borderline elevated bone metabolism; lactose intolerance was present in 16 patients (37%). CONCLUSION: Doctors should be aware of the possibility of major bone loss after chemotherapy with a risk of pathologic fracture. Vitamin D deficiency, calcium malnutrition, and lactose intolerance may potentiate the negative effects of chemotherapy, and should be considered in long-term patient management. LEVEL OF EVIDENCE: Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
Authors: J Dunst; S Ahrens; M Paulussen; C Rübe; W Winkelmann; A Zoubek; D Harms; H Jürgens Journal: Int J Radiat Oncol Biol Phys Date: 1998-09-01 Impact factor: 7.038
Authors: S Bielack; B Kempf-Bielack; D Schwenzer; T Birkfellner; G Delling; V Ewerbeck; G U Exner; N Fuchs; U Göbel; N Graf; U Heise; K Helmke; A R von Hochstetter; H Jürgens; R Maas; N Münchow; M Salzer-Kuntschik; J Treuner; U Veltmann; M Werner; W Winkelmann; A Zoubek; R Kotz Journal: Klin Padiatr Date: 1999 Jul-Aug Impact factor: 1.349
Authors: M E Ooms; P Lips; J C Roos; W J van der Vijgh; C Popp-Snijders; P D Bezemer; L M Bouter Journal: J Bone Miner Res Date: 1995-08 Impact factor: 6.741
Authors: Julie A Pasco; Margaret J Henry; Mark A Kotowicz; Kerrie M Sanders; Ego Seeman; John R Pasco; Hans G Schneider; Geoffrey C Nicholson Journal: J Bone Miner Res Date: 2004-01-19 Impact factor: 6.741
Authors: Magdalena Maria Gilg; Christine Wibmer; Dimosthenis Andreou; Alexander Avian; Petra Sovinz; Werner Maurer-Ertl; Per-Ulf Tunn; Andreas Leithner Journal: Clin Orthop Relat Res Date: 2014-04-29 Impact factor: 4.176
Authors: Se Won Lim; Ju Hyun Ahn; Aery Choi; Wan Hyeong Cho; Jun Ah Lee; Dong Ho Kim; Ju-Hee Seo; Jung Sub Lim Journal: Ann Pediatr Endocrinol Metab Date: 2016-03-31
Authors: Gerhard M Hobusch; Thomas M Tiefenboeck; Janina Patsch; Christoph Krall; Gerold Holzer Journal: Clin Orthop Relat Res Date: 2016-02-16 Impact factor: 4.176